Cosmos Health Inc. (COSM)
NASDAQ: COSM · IEX Real-Time Price · USD
0.650
+0.129 (24.81%)
At close: Apr 26, 2024, 4:00 PM
0.640
-0.010 (-1.52%)
After-hours: Apr 26, 2024, 7:52 PM EDT
Cosmos Health Revenue
Cosmos Health had revenue of $49.59M in the twelve months ending September 30, 2023, down -8.97% year-over-year. Revenue in the quarter ending September 30, 2023 was $12.82M with 6.72% year-over-year growth. In the year 2022, Cosmos Health had annual revenue of $50.35M, a decrease of -10.48%.
Revenue (ttm)
$49.59M
Revenue Growth
-8.97%
P/S Ratio
0.22
Revenue / Employee
$486,159
Employees
102
Market Cap
11.01M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2022 | 50.35M | -5.89M | -10.48% |
Dec 31, 2021 | 56.24M | 833.33K | 1.50% |
Dec 31, 2020 | 55.41M | 15.73M | 39.65% |
Dec 31, 2019 | 39.68M | 2.59M | 6.99% |
Dec 31, 2018 | 37.08M | 7.07M | 23.56% |
Dec 31, 2017 | 30.01M | 23.26M | 344.28% |
Dec 31, 2016 | 6.76M | 6.22M | 1,165.53% |
Dec 31, 2015 | 533.80K | -7.11M | -93.01% |
Dec 31, 2014 | 7.64M | 6.74M | 746.55% |
Dec 31, 2013 | 902.37K | - | - |
Dec 31, 2012 | 0 | - | - |
Jul 30, 2011 | 0 | - | - |
Jul 30, 2010 | 0 | - | - |
Jul 31, 2009 | - | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Guardion Health Sciences | 12.25M |
iCoreConnect | 8.15M |
Biomerica | 5.41M |
Can-Fite BioPharma | 743.00K |
Inhibikase Therapeutics | 260.50K |
Organovo Holdings | 242.00K |
Nexalin Technology | 110.75K |
China SXT Pharmaceuticals | 29.92K |
COSM News
- 8 days ago - Cosmos Health Receives Nasdaq Notice on Late Filing of Its Form 10-K - Accesswire
- 5 weeks ago - Cosmos Health Commences Development of Cloudscreen 2.0, the New Iteration of its Next Generation AI Drug Repurposing Platform - Accesswire
- 5 weeks ago - Cosmos Health To Receive Regulatory Approval for C-Scrub Disinfectant in the UK, Obtains Initial Purchase Order; Explores Opportunities Outside EU, Eyeing Global $36Bn+ Market - Accesswire
- 5 weeks ago - Cosmos Health Receives Regulatory Approval to Sell Sky Premium Life Products in $1.9Bn UAE Nutritional Supplements Market; Secures Initial Purchase Orders - Accesswire
- 2 months ago - Cosmos Health Successfully Completes Acquisition of Pharmatrade's Assets; Expects to Increase FY 2024 Annual Revenue by over $5 Million - Accesswire
- 2 months ago - Cosmos Health CEO, Greg Siokas, Purchases Shares in the Open Market, Showcasing His Confidence in the Company - Accesswire
- 3 months ago - Taglich Brothers Initiates Coverage of Cosmos Health Inc. - Accesswire
- 3 months ago - Cosmos Health Completes Acquisition of Cloudscreen, a Cutting-Edge AI Platform; Enters Lucrative $25Bn+ Global Drug Repurposing Market - Accesswire